Three-month, Single-center Study to Identify Biomarkers (Plasma Exosomal miRNAs) and Mechanism of Response (Basophil Transcriptome Analysis) to Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Biomarker; Pharmacodynamics
- 22 Jan 2019 Status changed from recruiting to completed.
- 27 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 27 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2018.